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ABSTRACT: Eﬀorts to develop inhibitors, activators, and eﬀectors of biological reactions using small molecule libraries are
often hampered by interference compounds, artifacts, and false positives that permeate the pool of initial hits. Here, we report the
discovery of a promising initial hit compound targeting the Fanconi anemia ubiquitin-conjugating enzyme Ube2T and describe
its biophysical and biochemical characterization. Analysis of the co-crystal structure led to the identiﬁcation of a contaminating
zinc ion as solely responsible for the observed eﬀects. Zinc binding to the active site cysteine induces a domain swap in Ube2T
that leads to cyclic trimerization organized in an open-ended linear assembly. Our study serves as a cautionary tale for screening
small molecule libraries and provides insights into the structural plasticity of ubiquitin-conjugating enzymes.
■ INTRODUCTION
Many diﬀerent mechanisms can lead to false positive signals
when screening for small molecules binding to a protein of
interest. Among them are compound aggregation, interference
with the detection method, covalent and nonspeciﬁc cross-
linking, redox reactions, or the presence of impurities.1 Several
molecules that yield false signals across diﬀerent assays are
known as PAINS (pan-assay interference compounds). Such
compounds have deﬁned structures and are repeatedly
identiﬁed and published as promising hits against diﬀerent
proteins; however, their activity does not depend on speciﬁc,
drug-like interactions with the protein and instead arises as a
result of a variety of artifacts.2 Some types of false positives are
easier to detect and discard. For instance, using orthogonal
assays is a common way to exclude interferences related to a
particular detection method, and using non-ionic detergents
can eﬀectively relieve enzyme inhibition by aggregated
compounds.3 In other cases, compound interference can be
more diﬃcult to recognize, especially when the observed eﬀect
is concentration-dependent and consistent across diﬀerent
orthogonal assays.
We recently reported a fragment screening against the
ubiquitin-conjugating enzyme Ube2T.4 Ubiquitin-conjugating
enzymes (E2s) possess a catalytic cysteine, which receives a
ubiquitin molecule from the E1 (ubiquitin-activating enzyme)
through a transthiolation reaction and, together with an E3
ligase, transfers it onto the lysine of a substrate. All E2s possess
a core catalytic domain (∼150 amino acids), known as the
UBC (ubiquitin-conjugating) fold, that contains a conserved
catalytic cysteine (Figure 1A). This domain is normally
composed of four α helices and four β strands, occasionally
enriched by insertion loops and N- or C-terminal extensions,
which are often intrinsically disordered.5,6 RING-type E3s
facilitate ubiquitin transfer by binding the E2s on a surface that
is distinct from the active site.7,8 This region comprises loops 1
and 2 and the ﬁrst α helix of the UBC fold.
Ube2T shares the canonical UBC fold and presents a C-
terminal extension (∼40 residues), which is not visible in any of
the published crystal structures.4,9,10 Ube2T speciﬁcally
interacts with the RING E3 ligase FANCL with a KD of ∼0.5
μM.10,11 This exclusive E2−E3 pair catalyzes the monoubiquiti-
nation of the heterodimeric FANCI/FANCD2 complex, which
is the key signaling event to activate the Fanconi anemia
pathway for DNA repair.12,13
Here, we report the detailed biophysical characterization and
optimization attempts for what seemed to be the most
promising hit compound of our fragment screening. The
eﬀects of this molecule were consistent and concentration-
dependent across a wide range of biophysical assays. Most of
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the synthesized analogues resulted in complete loss of binding,
even when modiﬁcations were minor. The crystal structure was
crucial for explaining the lack of a consistent structure−activity
relationship (SAR): the eﬀects of our hit compound were solely
due to a zinc contamination. Zinc induces an unprecedented
arrangement in Ube2T by binding at two diﬀerent sites on the
protein: the ﬁrst site mediates the formation of a domain-
swapped cyclic trimer, and the second site is responsible for the
arrangement of the trimers in an open-ended linear assembly.
Our study shows that the active site cysteine in Ube2T is
susceptible to modiﬁcation and reveals the plasticity of the E2
fold.
■ RESULTS AND DISCUSSION
Discovery of Compound 1 as a Potential Ube2T
Inhibitor. Compound 1 (Figure 1B) was identiﬁed as a hit in
our recently published fragment screening against the ubiquitin-
conjugating enzyme Ube2T.4 The initial orthogonal screens
using diﬀerential scanning ﬂuorimetry (DSF) and biolayer
interferometry (BLI) both yielded compound 1 as a very
promising hit showing a concentration-dependent eﬀect
(Figure S1). Although compound 1 acted as a destabilizer in
DSF, causing a decrease in Ube2T’s melting temperature (even
at low concentrations), we pursued this due to reports that
destabilizing agents can be conﬁrmed as true binders.4,14 In
BLI, association and dissociation responses were observed also
at the lowest concentration tested (2 μM), in contrast with
other fragments that did not show any binding at this
concentration.
Having identiﬁed 1 as the most potent hit of our fragment
screening, we were interested in characterizing it further and
exploring its mechanism of action.
In order to map its binding site, we performed HSQC
experiments using 15N-labeled Ube2TΔC (residues 1−154,
lacking the C-terminal ﬂexible tail).4 Upon addition of
increasing concentrations of compound 1 (100, 300, and 500
μM), several resonance peaks became weaker and ﬁnally
disappeared when a molar ratio of approximately 1:10 was
reached (500 μM 1; Figure S2). Disappearance of the peaks
suggested a tighter interaction of 1 compared to the other
fragments tested, which caused only moderate shifts at
millimolar concentrations. We conﬁrmed that the disappear-
ance of the peaks was due to a genuine and reversible binding
by dialyzing out compound 1 overnight. As expected, the
signals’ position in the free spectrum was restored after dialysis.
These residues were mapped onto the available Ube2T crystal
structures4,9,10 and appeared to be adjacent to the catalytic
cysteine (Figure 1C). At this site, however, no apparent pocket
was present. We therefore speculated that a structural
rearrangement needed to occur to accommodate a small
molecule binding.
In order to obtain more insights into compound 1 binding,
we performed isothermal titration calorimetry (ITC) experi-
ments (Figure 1D and Table S1) and found that 1 binds
Ube2T with a KD = 17.7 μM (LE = 0.41 kcal mol
−1), a rather
high aﬃnity for a fragment.
In order to assess whether the binding of 1 was competitive
with that of Ube2T cognate E3, we used a diﬀerent construct in
which Ube2T is fused to the RING domain of FANCL through
a linker between the two proteins (Ube2T−FANCLRING).
10 A
similar KD was obtained when 1 was titrated against the
Ube2T−FANCLRING fusion protein (Figure 1D), conﬁrming
that 1 binds to a diﬀerent site. In contrast, binding was
completely lost when Ube2T carries a ubiquitin molecule at the
active site (Ube2T−Ub, where ubiquitin is linked through an
isopeptide bond to the C86K-K91R-K95R mutant Ube2T).
This was consistent with the observation that the compound 1
binding site is adjacent to the catalytic cysteine (C86). We next
Figure 1. Biophysical and biochemical characterization of compound 1. (A) Ube2T structure showing the typical E2 UBC fold. (B) Chemical
structure of 1. (C) 1 binding site determined by protein-observed NMR and mapped on the Ube2T crystal structure. Residues colored in magenta
correspond to 15N-Ube2T HSQC resonances aﬀected by the addition of 1 (see also Figure S2). (D) ITC titrations of 1.5 mM 1 against ∼50 μM of
the diﬀerent Ube2T constructs indicated; details are reported in Table S1. (E) Representative Coomassie stained gel of the biochemical assay
monitoring the ubiquitin-charging of Ube2T in the presence of compound 1. The left lanes show a control reaction in which Ube2T is absent.
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investigated if 1 was able to aﬀect Ube2T enzymatic activity
using a biochemical assay. This assay monitors the ﬁrst step of
the ubiquitination cascade, which is the ability of Ube2T (the
E2) to be ubiquitin-charged by the E1 on the catalytic cysteine
via a transthiolation reaction. As shown in Figure 1E, in the
absence of compound 1, Ube2T is charged and autoubiquiti-
nates itself as previously reported.12 Addition of 100 μM 1
almost completely abolished Ube2T charging, and this eﬀect
was concentration-dependent. In contrast, the same concen-
trations did not aﬀect the E1−Ub charging in the absence of
Ube2T (Figure 1E), indicating that 1 speciﬁcally inhibits
Ube2T−Ub charging by the E1.
These results, together with the biophysical characterization
reported above, suggested that 1 was a very encouraging hit
compound able to compromise the catalytic activity of Ube2T
and therefore suitable for further optimization.
Synthesis of Compound 1 Analogues. In order to
optimize the binding aﬃnity of compound 1, we set up
crystallization experiments aimed at determining the mode of
binding of 1. In parallel, we designed a small library of
compounds (2−14) to begin to evaluate structure−activity
relationships (Chart 1).
First, the amidine moiety was removed or replaced by a
primary amine, an amide, a sulfonamide, or a carboxylate
(derivatives 2−6). Compounds 2, 3, 5, and 6 were
commercially available. Amide 4 was prepared from commer-
cially available carboxylic acid 3 and ammonium chloride by
HATU/N,N-diisopropylethylamine (DIPEA) mediated amide
coupling. None of the compounds showed binding in ITC and
DSF, suggesting that the amidine group is an essential feature
for binding. Diﬀerent analogues were subsequently designed
maintaining the amidine functionality intact and introducing
modiﬁcations in the biaryl part of the molecule (Chart 1).
Non-commercially available amidines 10 and 11 were
synthesized in-house (Scheme 1) from 6-ﬂuoronicotinonitrile
15, which was reacted with the appropriate pirrolidine and
DIPEA in acetonitrile at 90 °C overnight, obtaining nitriles 16
and 17 in good yields after ﬂash column chromatography
puriﬁcation. Nitriles 16 and 17 were treated with an excess of
anhydrous gaseous hydrochloric acid in methanol to obtain
imino ether hydrochlorides, which were treated with 7 M
ammonia solution in methanol to obtain amidines 10 and 11
(50−65% yield after preparative HPLC).
Chart 1. Chemical Structures of Compound 1 Analoguesa
aDerivatives 1, 2, 3, 5, 6, 8, 9, and 12 were purchased from a commercial vendor. 4, 7, 10, 11, 13, and 14 were synthesized.
Scheme 1. Synthesis of Amidines 7, 10, 11, 13, and 14
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Nitriles 18−20 were reacted with sodium methoxide in
methanol at room temperature (Scheme 1) until full
conversion to the corresponding imino ethers was observed
by LC−MS. Reaction of the imino ethers (not isolated) with
ammonium chloride aﬀorded the expected amidines 7, 13, and
14, which were ﬁnally puriﬁed by HPLC.
Compounds 7−14 were tested in DSF and ITC, and
surprisingly only derivatives 9 and 13 showed a concentration-
dependent eﬀect in DSF (Figure S3). Only for compound 9
was the KD measurable by ITC, although the aﬃnity is much
weaker (∼500 μM). Compound 13 lacks the two methyl
groups on the pyrazole ring, whereas 9 has a saturated
pyrrolidine ring replacing the pyrazole. However, when the
pyrrolidine moiety is 2- or 3-methyl-substituted (derivatives 10
and 11) or when it is replaced by a piperidine ring (compound
12), binding is again completely abolished.
Co-crystal Structure Reveals a Metal-Mediated
Oligomer. The rather ﬂat SAR results raised some concerns
regarding compound 1. Although quality control documents
were provided by the commercial vendor, we repeated NMR
and HRMS analyses, ﬁnding them in agreement with the
declared structure (see Supporting Information). Despite
having identiﬁed the binding site by protein-observed NMR
and conﬁrmed it with solid binding data, the molecular details
of the compound 1−Ube2T interaction were missing. Only a
co-crystal structure could help to understand why any minor
change of the original structure of compound 1 led to a
complete loss in binding. For this reason, we pursued multiple
co-crystallization attempts using diﬀerent Ube2T constructs,
including the full-length protein (1−197), Ube2TΔC (1−154),
and the Ube2T−FANCLRING fusion construct.10 After many
unsuccessful attempts, well-diﬀracting crystals of Ube2TΔC with
compound 1 in a 1:5 molar ratio were eventually obtained. We
solved the crystal structure at 1.85 Å (PDB ID 5OJJ; Table S2)
and discovered an unexpected arrangement of Ube2T
molecules.
Contrary to all the other Ube2T structures in which Ube2T
is monomeric (Figure 1A), our crystal structure contains six
molecules in the asymmetric unit organized in two cyclic
trimers (Figure 2). Each monomer has adopted an unusual
conformation whereby the N-terminal α1-helix and β1-strand
(ﬁrst ∼30 residues) have moved onto the nearby molecule of
the trimer with a cyclic organization (chain A onto B, chain B
onto C, chain C onto A; Figure 2A,B). This structural
rearrangement is called “domain swap”: protein molecules
exchange secondary structure elements to form an intertwined
oligomer in which the overall fold of each monomer is
maintained, with the exception of the hinge loop connecting
the part that is exchanged.15 In our structure, the hinge loop is
formed by residues Q26−D33. Interestingly, a domain swap of
Figure 2. Zinc-mediated Ube2TΔC oligomerization. (A) Comparison between the usually observed Ube2T monomeric structure and the domain-
swapped form. (B) Structure of the domain-swapped cyclic trimer held together by Zn2+ ions (PDB ID 5OJJ). The domain swap involves helix α1
and strand β1 of the three subunits. Each monomer binds a Zn2+ ion at the catalytic cysteine (Zinc site 1), connecting two monomers. (C) A second
zinc binding site (Zinc site 2) is formed on the trimer by residues D127 of each of the three subunits and is responsible for joining the trimers, with
H12 from a diﬀerent trimer completing the tetrahedral coordination. (D) Schematic representation of the zinc-induced domain swap and
oligomerization. (E) Surface representation of the open-ended linear assembly of Ube2TΔC trimers.
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the same secondary structure elements has also been observed
for a diﬀerent E2, Ube2W (PDB entry 2A7L).9 Ube2W,
however, forms a reciprocal dimer instead of a cyclic trimer
(Figure S4).
Close analysis of the reﬁned structure revealed that no
organic molecule corresponding to compound 1 was bound to
the protein at the catalytic site, as suggested by the HSQC
experiments, or anywhere else on the surface. However, a
strong and unexplained density, which suggested a metal ion,
was connected to the catalytic cysteine (C86) (Figures S5 and
S6). Given the coordination geometry and the nature of the
chelating residues, we modeled a zinc ion. The tetrahedral
coordination is completed by the S atom of C86, the ε amino
group of K91, an acetate molecule from the crystallization
buﬀer and by the π nitrogen of H150 from a diﬀerent Ube2T
molecule (Zinc site 1, Figure 2B). This zinc chelation involving
two diﬀerent Ube2T monomers is responsible for the
formation of the domain-swapped cyclic trimer (Figure 2B, D).
Interestingly, when the trimer is formed, D127 residues from
each Ube2T monomer come close together and chelate another
Zn2+ ion through one oxygen atom of the carboxylate, further
stabilizing the trimer assembly. At this second Zn2+ binding site
(Zinc site 2, Figure 2C), the tetrahedral coordination is
completed by the τ nitrogen of H12 from a diﬀerent trimer,
leading to an open ended linear assembly of trimers (Figure
2D, E).
Investigating Zinc Contamination in Our Compound
Series. In our structure, four zinc ions are bound to each
Ube2T trimer; however, no zinc salt is present in the
crystallization buﬀer or is used during Ube2T expression and
puriﬁcation. Moreover, while performing co-crystallization
trials, we noticed a direct correlation between the concentration
of compound 1 and the number of crystals formed, with no
crystallization occurring when 1 was absent. These observations
led us to hypothesize that zinc may be present as a contaminant
of the purchased compound 1 powder and that the observed
biophysical and biochemical eﬀects of 1 could be attributed to
the presence of zinc. To test this hypothesis, we repeated the
ITC experiments in the presence of a chelating agent.
Remarkably, no binding was observed in the presence of 2
mM EDTA in the ITC buﬀer (Figure 3A), conﬁrming that the
exceptionally good activity of compound 1, found during our
fragment screening, is exclusively due to zinc contamination of
the original powder.
Furthermore, when ZnCl2 was titrated against Ube2T in
ITC, the isotherm was almost identical to the one obtained for
compound 1 (Figure 3A).
To further conﬁrm the presence of zinc, we used a
colorimetric reagent known as Zincon (2-carboxy-2′-hydroxy-
5′-sulfoformazylbenzene), which has been used as a chromo-
phore for the quantiﬁcation of both zinc and copper ions in
aqueous solution.16 Zincon conﬁrmed the presence of diﬀerent
amount of Zn2+ in compounds 1, 9, and 13 (Figure 3B; 12 was
used as a negative control), proportional to their “potency” in
DSF and ITC, ultimately explaining the ﬂat and curious SAR of
this compound series.
■ SUMMARY AND CONCLUSIONS
False positives are known to permeate the initial pool of hits
from many compound screenings. To mitigate this eﬀect,
multiple assays are often performed in parallel to identify
genuine binders and exclude interferences related to a single
detection method, eﬀects that can arise from aggregation or
covalent and nonspeciﬁc cross-linking. In this context, our
compound 1 case was particularly challenging. We detected
binding in DSF and BLI, where we observed a rather normal
association and dissociation proﬁle. We mapped the binding
site through protein-observed NMR spectroscopy, and we
measured the binding aﬃnity by ITC. Through ITC, we were
also able to estimate the stoichiometry of interaction, which
appeared to be close to 1, as one would expect from a genuine
binder. Compound 1 binding resulted in inhibition of Ube2T
enzymatic activity, as demonstrated using a biochemical assay.
All of these results obtained for compound 1 were
concentration-dependent and consistent, until the unusual
SAR raised the ﬁrst suspicions. At last, only the crystal structure
could tell us what the real “active ingredient” of our powder
was, which was not detectable through routine LC−MS and
NMR quality control.
Our story serves as a cautionary tale for screening small
molecule libraries, in particular when trying to target ubiquitin-
conjugating enzymes (or cysteine-containing enzymes in
general). Hermann et al. have also reported that zinc and
other metal impurities, often derived from the synthetic
procedures, may aﬀect a number of targets or assays.17 The
eﬀect of contaminating metals can be recognized by repeating
certain assays in the presence of chelating agents (such as
EDTA) when this is compatible with the assay setup and the
Figure 3. Conﬁrmation of zinc contamination and binding eﬀect. (A)
The superposition of ZnCl2 and 1 titration against Ube2T shows an
almost identical proﬁle. Binding is lost when 1 is titrated against
Ube2T in the presence of EDTA. (B) Zincon colorimetric assay
performed on compounds 1, 9, 13, and 12 shows a correlation
between the amount of zinc present and the observed binding potency.
Water and ZnCl2 are used as references for the observed color
changes.
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protein structure (e.g., chelating agents should be avoided when
structural or catalytic metals are part of the protein of interest).
In our study, the unexpected structural arrangement induced
by zinc opens up new prospects. Although the micromolar
aﬃnity of Zn toward Ube2T excludes a physiological relevance
of this interaction, analysis of the zinc-induced oligomerization
may provide an interesting model for designing metal mediated
protein−protein interactions. Indeed, work from several
research groups has been focused on controlling protein self-
assembly into polymeric architectures by designing metal
binding sites,18−21 which add strength, directionality, and
selectivity to the interaction, as metal chelation geometries and
preferences are well understood.22
Another important feature of our structure is the domain
swap of the N-terminal α1-helix and β1-strand of Ube2T, which
is also observed for a diﬀerent E2, Ube2W.9 Previous studies
have indeed highlighted that the swaps adopted by members of
a protein family are characteristic traits of the protein fold.23,24
Domain swap has been often associated with a high degree of
structural plasticity; as an example, GB1 protein (immunoglo-
bulin-binding domain B1 of streptococcal protein G) has been
named “protein contortionist” for its ability to form a swapped
dimer, a tetramer, or an amyloid ﬁbril upon mutation of speciﬁc
residues.25−27
Although the biological role of protein domain swapping
remains elusive, it has attracted much interest because of its
potential involvement in protein misfolding and aggregation
processes associated with amyloid formation and prion
diseases.28−30
Diﬀerent mechanisms have been proposed for the monomer
to oligomer transition. These include formation of an “open”
intermediate or a transition in which conformational changes of
individual monomers and their association are tightly coupled
to minimize solvent exposure.24 Another hypothesis is the
formation of an unfolded state prior to oligomer assembly.
Irrespective of the domain swap, diﬀerent changes in the
environmental conditions (pH, temperature, salt ions) may
destabilize the monomeric folded state of a protein and trigger
aggregation.31 In our system, we observed signiﬁcant
destabilization of Ube2T in the presence of zinc, with decrease
of the protein unfolding temperature in DSF. We therefore
hypothesize that zinc binding at the catalytic cysteine promotes
the domain swap either by an allosteric mechanism or by
inducing an intermediate unfolded state. The observed
structural plasticity for Ube2T and Ube2W, together with the
induced allosteric eﬀect across the UBC fold proposed here for
Ube2T, might emerge as a common characteristic for the
ubiquitin-conjugating enzyme family.
■ EXPERIMENTAL SECTION
Protein Expression and Puriﬁcation. All Ube2T constructs were
expressed and puriﬁed as described previously.4,10 In order to generate
a stable ubiquitin-loaded Ube2T, the catalytic cysteine was mutated to
a lysine (C86K) and the two lysines close to the catalytic site were
mutated to arginines (K91R and K95R). Ubiquitin was then
enzymatically linked to K86 through an isopeptide bond between
ubiquitin’s C-terminus and the ε amino group of K86, as described by
Plechanovova ́ et al.32
Fragment Screening. Our fragment screening cascade consisted
of a combination of biophysical methods. DSF, BLI, and protein-
observed NMR were performed as described previously.4 However, for
DSF and HSQC experiments, lower compound concentrations were
used compared to the other fragments reported in our previous study.4
For the DSF experiments, 40 μL samples were prepared in duplicates
using 5 μM Ube2T, 2.5× SYPRO orange in 100 mM Tris pH 8.0, 100
mM NaCl, 0.25 mM TCEP, and a compound concentration ranging
from 5 μM to 5 mM. The samples were heated from 25 to 95 °C with
increments of 1 °C/min, and ﬂuorescence was measured at each step.
Data analysis was performed as described by Niesen et al.33
Nuclear Magnetic Resonance Spectroscopy. [1H−15N]-
HSQC spectra were recorded on 50 μM 15N-Ube2TΔC with increasing
concentrations of compound 1 (100, 300, and 500 μM) as described
previously.4 A superposition of the apoprotein spectrum with the
spectrum recorded at the highest compound 1 concentration tested is
shown in Figure S2. Compound 1 was then dialyzed out overnight in
the same buﬀer used for the described NMR experiments (50 mM
potassium phosphate pH 6.8, 85 mM NaCl, 1 mM DTT). After
dialysis, a new HSQC spectrum was recorded, showing that the
position of the signals in the apo Ube2T spectrum was restored.
Isothermal Titration Calorimetry. All experiments were carried
out using a MicroCal PEAQ-ITC (Malvern) and analyzed using
MicroCal PEAQ-ITC analysis software. All titrations were performed
at 25 °C while stirring at 750 rpm in a buﬀer containing 100 mM Tris
pH 8.0, 100 mM NaCl, and 0.5 mM TCEP. A control experiment of
titrant into buﬀer was performed in order to account for the heat of
dilution. All titrations were repeated at least twice with similar results.
For all titrations, an approximate protein concentration of 50 μM was
used. Detailed concentrations and thermodynamic parameters per
each ﬁtted ITC experiment are reported in Table S1.
Ube2T Charging Assay. Ube2T charging reactions (20 μL)
contained 20 μM ubiquitin, 0.2 μM recombinant human E1, 10 μM
Ube2T, and 5 mM ATP. Reactions were carried out for 10 min at 30
°C and terminated with non-reducing LDS loading buﬀer. The
samples were resolved by SDS-PAGE, and the gels were Coomassie
stained (Figure 1E). All experiments were repeated at least twice with
similar results.
Synthetic Procedures. All chemicals, unless otherwise stated,
were commercially available and used without further puriﬁcation.
Reactions were magnetically stirred; commercially available anhydrous
solvents were used. Flash column chromatography (FCC) was
performed using a Teledyne Isco Combiﬂash Rf or Rf200i; prepacked
RediSep Rf normal phase disposable columns were used. NMR spectra
were recorded on a Bruker Ascend 400. Chemical shifts are quoted in
ppm and referenced to the residual solvent signals: 1H δ = 7.26 ppm
(CDCl3), 4.79 ppm (D2O), 2.50 ppm (DMSO-d6);
13C δ = 77.2 ppm
(CDCl3), 39.5 ppm (DMSO-d6); signal splitting patterns are described
as singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet
(q), multiplet (m), and broad (br). Coupling constants (JH−H) are
measured in Hz. High-resolution mass spectra (HRMS) were recorded
on a Bruker microTOF. Low-resolution MS and analytical HPLC
traces were recorded on an Agilent Technologies 1200 series HPLC
connected to an Agilent Technologies 6130 quadrupole LC−MS,
connected to an Agilent diode array detector. Preparative HPLC was
performed on a Gilson preparative HPLC system with a Waters X-
Bridge C18 column (100 mm × 19 mm; 5 μm particle size). Elution
conditions are reported in the general methods. The purity of all
compounds was analyzed by HPLC−MS (ESI) and was >95%.
6-(3,5-Dimethyl-1H-pyrazol-1-yl)nicotinamide (4). To a solution
of 3 (20 mg, 0.092 mmol) in DMF (4 mL) were added HATU (53
mg, 0.138 mmol), NH4Cl (10 mg, 0.184 mmol), and DIPEA (63 μL,
0.368 mmol). The reaction mixture was stirred at room temperature
for 3 h; the solvent was then removed under reduced pressure. The
crude was dissolved in DCM (5 mL) and washed with water (2 mL),
and the organic layer was dried over anhydrous MgSO4. DCM was
removed under reduced pressure, and the crude was dissolved in
methanol and puriﬁed by preparative HPLC (gradient of 5−95%
acetonitrile in water with 0.1% formic acid over 10 min, ﬂow 25 mL/
min) and freeze-dried to obtain the title compound as a white powder,
12 mg, 60% yield. 1H NMR (400 MHz, DMSO) δ: 8.86 (d, J = 2.7 Hz,
1H), 8.31 (dd, J = 2.5, 8.6 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 6.15 (s,
1H), 2.59 (s, 3H), 2.19 (s, 3H). 13C NMR (101 MHz, DMSO) δ:
166.3, 155.0, 150.2, 147.7, 141.9, 138.6, 127.1, 114.6, 110.3, 15.1, 13.9.
HRMS m/z calcd for C11H12N4O: 216.1011, found 217.1032 [M +
H+].
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4-(3,5-Dimethyl-1H-pyrazol-1-yl)benzimidamide, Formate Salt
(7). Prepared accordingly to general method A. 19 mg, 37% yield,
white solid. 1H NMR (400 MHz, D2O) δ: 8.43 (s, 1H), 7.88 (d, J = 8.6
Hz, 2H), 7.58 (d, J = 8.9 Hz, 2H), 6.19 (s, 1H), 2.30 (s, 3H), 2.25 (s,
3H). 13C NMR (101 MHz, D2O) δ: 170.9, 165.8, 151.3, 143.2, 142.1,
129.0, 126.6, 124.6, 108.1, 12.1, 11.5. HRMS m/z calcd for C12H14N4:
214.1218, found 215.1227 [M + H+].
6-(2-Methylpyrrolidin-1-yl)nicotinimidamide (10). Prepared ac-
cordingly to general method B. 32 mg, 42% yield, white solid. 1H
NMR (400 MHz, D2O) δ: 8.40 (d, J = 2.6 Hz, 1H), 8.11 (dd, J = 2.1,
9.7 Hz, 1H), 7.28−7.15 (m, 1H), 4.39 (br. s, 1H), 3.83−3.76 (m, 1H),
3.58 (br. s, 1H), 2.32−2.14 (m, 3H), 1.96−1.90 (m, 1H), 1.29 (d, J =
6.4 Hz, 3H). 13C NMR (101 MHz, D2O) δ: 165.7, 162.5, 139.3, 138.3,
114.0, 111.9, 57.0, 48.2, 31.8, 22.3, 17.2. HRMS m/z calcd for
C11H16N4: 204.1375, found 205.1359 [M + H
+].
6-(3-Methylpyrrolidin-1-yl)nicotinimidamide (11). Prepared ac-
cordingly to general method B. 30 mg, 40% yield, white solid. 1H
NMR (400 MHz, D2O) δ: 8.36 (dd, J = 0.6, 2.3 Hz, 1H), 8.06 (dd, J =
2.4, 9.8 Hz, 1H), 7.09 (d, J = 9.2 Hz, 1H), 3.79 (br. s, 2H), 3.67−3.59
(m, 1H), 3.22 (br. s, 1H), 2.56−2.48 (m, 1H), 2.30−2.22 (m, 1H),
1.81−1.72 (m, 1H), 1.12 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz,
D2O) δ: 162.6, 151.1, 139.1, 138.7, 113.5, 111.9, 55.4, 48.2, 32.9, 32.2,
16.4. HRMS m/z calcd for C11H16N4: 204.1375, found 205.1367 [M +
H+].
6-(1H-Pyrazol-1-yl)nicotinimidamide, Formate Salt (13). Pre-
pared accordingly to general method A. 16 mg, 37% yield, white
solid. 1H NMR (400 MHz, D2O) δ: 8.79 (d, J = 2.0 Hz, 1H), 8.55 (d, J
= 3.1 Hz, 1H), 8.44 (s, 1H), 8.32 (dd, J = 2.4, 8.7 Hz, 1H), 7.96 (d, J =
9.1 Hz, 1H), 7.91 (d, J = 1.6 Hz, 1H), 6.66 (t, J = 2.1 Hz, 1H). 13C
NMR (101 MHz, D2O) δ: 171.0, 164.0, 153.7, 147.9, 144.3, 139.5,
129.1, 122.4, 112.7, 109.5. HRMS m/z calcd for C9H9N5: 187.0858,
found 188.0921 [M + H+].
6-(2-Methyl-1H-imidazol-1-yl)nicotinimidamide, Formate Salt
(14). Prepared accordingly to general method A. 22 mg, 45% yield,
white solid. 1H NMR (400 MHz, D2O) δ: 8.98 (d, J = 2.5 Hz, 1H),
8.48 (dd, J = 2.5, 8.6 Hz, 1H), 7.84 (d, J = 8.6 Hz, 1H), 7.62 (d, J = 1.7
Hz, 1H), 7.20 (d, J = 1.7 Hz, 1H), 2.62 (s, 3H). 13C NMR (101 MHz,
D2O) δ: 171.0, 163.9, 152.6, 148.3, 146.2, 140.1, 125.0, 124.5, 120.5,
118.9, 13.3. HRMS m/z calcd for C10H11N5: 201.1014, found
202.1049 [M + H+].
6-(2-Methylpyrrolidin-1-yl)nicotinonitrile (16). Prepared accord-
ingly to general method C. 72 mg, 77% yield, white solid. 1H NMR
(400 MHz, CDCl3) δ: 8.39 (dd, J = 0.7, 2.3 Hz, 1H), 7.54 (dd, J = 2.5,
9.0 Hz, 1H), 6.33 (d, J = 9.0 Hz, 1H), 4.21 (br. s, 1H), 3.59−3.55 (m,
1H), 3.42−3.35 (m, 1H), 2.18−2.00 (m, 3H), 1.82−1.73 (m, 1H),
1.22 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ: 157.3,
153.2, 139.0, 119.3, 106.3, 94.8, 53.6, 47.2, 32.7, 23.0, 18.9. MS m/z
calcd for C11H13N3: 187.1, found 188.1 [M + H
+].
6-(3-Methylpyrrolidin-1-yl)nicotinonitrile (17). Prepared accord-
ingly to general method C. 69 mg, 74% yield, white solid. 1H NMR
(400 MHz, CDCl3) δ: 8.39 (dd, J = 0.7, 2.3 Hz, 1H), 7.55 (dd, J = 2.3,
8.9 Hz, 1H), 6.31 (dd, J = 0.8, 9.0 Hz, 1H), 3.74−3.44 (m, 3H), 3.02
(br. s, 1H), 2.46−2.37 (m, 1H), 2.21−2.12 (m, 1H), 1.70−1.61 (m,
1H), 1.14 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ: 157.6,
153.1, 139.0, 119.2, 106.0, 95.0, 54.0, 46.8, 33.2, 17.9. MS m/z calcd
for C11H13N3: 187.1, found 188.1 [M + H
+].
General Method A. To a mixture of nitrile (0.24 mmol) and
methanol (0.5 mL) in a microwave vial equipped with rubber septum
and magnetic stirrer was added a solution of 0.5 M sodium methoxide
in methanol (0.5 mL, 0.25 mmol) under a nitrogen atmosphere. The
mixture was stirred at room temperature overnight. LC−MS analysis
showed complete conversion of the nitrile to the imino ether.
Ammonium chloride (16 mg, 0.30 mmol) was added, and the solution
was stirred for 8 h at 40 °C. Solvent was removed under reduced
pressure, and the resulting solid was dissolved in methanol, puriﬁed by
preparative HPLC (gradient of 5−95% acetonitrile in water with 0.1%
formic acid over 10 min, ﬂow 25 mL/min), and freeze-dried.
General Method B. A solution of nicotinonitrile 16 or 17 (0. 37
mmol) in methanol (4 mL) was treated with gaseous anhydrous
hydrochloric acid for 15 min at 0 °C, and the reaction mixture was left
at room temperature for 3 h. Volatile components were removed by
means of a nitrogen stream, and the resulting solid was dried under
vacuum. The white solid was dissolved in 2 mL of 7 N ammonia in
methanol, transferred to a microwave vial, sealed, and left at room
temperature for 24 h. The solvent was removed under reduced
pressure, and the resulting solid was dissolved in methanol, puriﬁed by
preparative HPLC (gradient of 5−70% acetonitrile in water with 0.1%
ammonia over 10 min, ﬂow 25 mL/min), and freeze-dried.
General Method C. To a solution of 6-ﬂuoronicotinonitrile (61 mg,
0.5 mmol) in acetonitrile (0.5 mL) in a microwave vial were added the
desired methylpyrrolidine (0.75 mmol) and DIPEA (261 μL, 1.5
mmol). The tube was sealed and heated at 90 °C overnight. The
solvent and volatile components were removed under reduced
pressure, and the crude mixture was puriﬁed by FCC over silica
using heptane/ethyl acetate (8:2) as the eluent mixture.
Crystallization and Structure Determination. The co-crystals
were obtained by sitting drop vapor diﬀusion using 19.5 mg/mL
Ube2TΔC (residues 1−154) and 5 mM compound 1 in a buﬀer
containing 0.1 M Tris pH 8.0, 0.1 M NaCl, and 0.25 mM TCEP. This
solution was mixed 1:1 (1.5 μL + 1.5 μL) with the crystallization buﬀer
containing 10% PEG3350, 0.2 M calcium acetate, and 0.1 M Tris pH
8.5 and equilibrated against 0.5 mL of reservoir solution at 20 °C.
Crystals appeared within a few hours. Crystals were cryoprotected with
a solution containing 20% PEG3350, 0.2 M magnesium acetate, and
0.1 M Tris pH 8.5 and ﬂash frozen in liquid nitrogen. Data were
collected at Diamond Light Source (i04-1 beamline) at 0.9282 Å
wavelength and processed using XDS,34 POINTLESS,35 and
AIMLESS36 from the CCP4 program suite37 to a resolution limit of
1.85 Å (Table S2). The structure was solved by molecular replacement
using PDB entry 1YH29 as a search model in MOLREP.38 The ﬁrst 32
amino acids were then deleted and manually rebuilt in Coot39 in order
to account for the domain swap that was unambiguous at such
resolution. The domain-swapped monomer was used again as a search
model in MOLREP38 and further reﬁned using Refmac540 and Coot.39
The quality of the model was checked using MolProbity.41 Zinc
binding sites were validated using CheckMyMetal.42
Zincon Assay. Zincon reagent was prepared by dissolving 4.35 mg
of Zincon (Na+ salt) in 200 μL of 0.5 M NaOH and then diluting it to
5 mL with water. In order to assess zinc contamination, we diluted this
stock solution 1:40 in 50 mM CHES pH 9.0 (orange solution) and
added the analyzed compound at a ﬁnal concentration of 2.5 mM. A
clear color change to a blue solution was appreciable for those
compounds contaminated with zinc (Figure 3B).
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